Small Molecule Videos

31. Lonza Advanced Synthesis Capabilities Update February 2026: AI Drug Development 3/2/2026

    Learn how our scientists accurately predict and identify the most stable cocrystal forms by leveraging advanced machine learning models, enhancing efficiency and reducing development risks.

32. Grace Capabilities Update February 2026: AI Drug Development 3/2/2026

    Discover support for your next small molecule drug substance program and learn how artificial intelligence and machine learning tools can be applied to accelerate API development.

33. Re-Thinking ASD Development: When Your Molecule Breaks The Rules 2/26/2026

    A solvent‑free, fusion‑based approach streamlines amorphous solid dispersion development, enabling rapid early screening, improved performance, and sustainable manufacturing.

34. From Brick Dust To Breakthrough: The Power Of Enabled Formulation 2/26/2026

    Enabled formulation strategies transform poorly soluble, highly lipophilic molecules into viable oral products by improving exposure, reducing burden, and ensuring manufacturable pathways.

35. From Molecule To Milestone: Fast Track Formulation 2/26/2026

    Fast‑track, data‑driven formulation strategies align early decisions with long‑term goals, enabling First‑in‑Human progress while reducing risk, avoiding rework, and supporting manufacturable development.

36. Navigating Complexity: Tailored Analytical & Preclinical Services 2/26/2026

    Tailored analytical and preclinical strategies identify risk early, integrate data-driven insight, and streamline formulation planning to accelerate timelines and position complex molecules for scalable, successful development.

37. Inside AustinPx: Live Company Overview 2/26/2026

    An inside look at a development partner's approach to guiding drug programs, using advanced formulation technology and integrated services to support scalable, high‑performance oral dosage development.

38. Step Inside The Power Of KinetiSol™ 2/26/2026

    Step inside the power of KinetiSol™. This video showcases our KinetiSol Large Scale Commercial Processing Equipment in action, producing amorphous solid dispersions at rates up to 20 kg per hour.

39. Concept To Market: Scaling And Manufacturing Semi-Solid Topical Drugs 2/23/2026

    Learn how formulation, processing, and scale‑up choices impact the stability, structure, and performance of semi‑solid topicals while ensuring consistent quality through development.

40. What Defines Excellence In CMC Analytics? 2/21/2026

    In this podcast, our Chief Scientific Officer, Daniel Galbraith, shares candid insights into what separates operational vendors from true scientific collaborators.